Domov › Metastatski rak › North Carolina › Durham
Klinične študije za Metastatski rak v Durham, NC
33 študij za Metastatski rak išče udeležence na lokacijah v Durham in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Vključevanje udeležencevFaza 1/2
- Avenzo Therapeutics Recruiting Site, Chapel Hill · 10 mi stran
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Vključevanje udeležencevFaza 2
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Duke University, Durham
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Vključevanje udeležencevFaza 2/3
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi stran
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Vključevanje udeležencevFaza 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Vključevanje udeležencevFaza 2
- Duke Cancer Institute, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Vključevanje udeležencevFaza 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi stran
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi stran
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Vključevanje udeležencevFaza 3
- Duke Cancer Institute, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Vključevanje udeležencevFaza 3
- University of North Carolina Medical Center, Chapel Hill · 10 mi stran
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi stran
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Vključevanje udeležencevFaza 1
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · 10 mi stran
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Duke University, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Vključevanje udeležencev
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi stran
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Vključevanje udeležencevFaza 1
- Duke Cancer Center, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Vključevanje udeležencevFaza 1
- Research Site, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Vključevanje udeležencevFaza 1
- Duke Cancer Center, Durham
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Vključevanje udeležencevFaza 1/2
- Duke University Medical Center, Durham
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
Vključevanje udeležencevOpazovalna študija
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi stran
UNC Metastatic Cancer Radiation Therapy Registry
Vključevanje udeležencevOpazovalna študija
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi stran
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Vključevanje udeležencevFaza 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi stran
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Vključevanje udeležencevFaza 2/3
- Durham VA Medical Center, Durham, NC, Durham
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Vključevanje udeležencevFaza 2/3
- Duke University Medical Center, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Vključevanje udeležencevFaza 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Vključevanje udeležencevFaza 1
- Duke Cancer Institute, Durham
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Vključevanje udeležencevFaza 3
- Duke University, Durham
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Vključevanje udeležencevOpazovalna študija
- Durham Veterans Administration Health Care System (DVAHCS), Durham
- Duke University Medical Center, Durham
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Vključevanje udeležencevFaza 1
- Duke Cancer Center, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Vključevanje udeležencevFaza 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi stran
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Duke University Medical Center - Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi stran
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Vključevanje udeležencevFaza 3
- Duke University - Trent Center, Durham
A Study of NX-1607 in Adults With Advanced Malignancies
Vključevanje udeležencevFaza 1
- University of North Carolina, Chapel Hill · 10 mi stran
Študije za Metastatski rak v drugih mestih
- Houston, TX104 študij
- New York City, NY93 študij
- Nashville, TN70 študij
- Boston, MA63 študij
- Los Angeles, CA57 študij
- St. Louis, MO54 študij
- Arlington, VA53 študij
- Philadelphia, PA46 študij
- Chicago, IL45 študij
- San Antonio, TX44 študij
- Washington, DC43 študij
- Dallas, TX42 študij
Druge študije v Durham
- Rak dojke64 študij
- Rak (vse vrste)58 študij
- Nemalicelični pljučni rak39 študij
- Množni mielom37 študij
- Akutna mieločna levkemija33 študij
- Rak prostate32 študij
- Rak pljuč32 študij
- Kolorektalni rak28 študij
- Rak jajčnikov27 študij
- Kronična limfocitna levkemija27 študij
- Srčno popuščanje26 študij
- Rak trebušne slinavke24 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.